Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16166135 | 0.93 | CYP11B2 (0.33) | CYP11B2MEN1KMT2AARS1PR1 | |
| SCHEMBL15649948 | 0.88 | CYP11B2 (0.34) | CYP11B2MEN1KMT2ATP53KDM4E | |
| SCHEMBL16166144 | 0.86 | CYP11B2 (0.33) | CYP11B2MEN1KMT2AARKDM4E | |
| SCHEMBL15694716 | 0.84 | KMT2A (0.36) | CYP11B2MEN1KMT2ATP53KDM4E | |
| SCHEMBL10080603 | 0.82 | SOAT1 (0.33) | KDM4EALDH1A1MAPK1S1PR1 | |
| SCHEMBL3342398 | 0.78 | TEAD3 (0.39) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12816036 | 0.78 | SCN1A (0.42) | MEN1KMT2ATP53KDM4EALDH1A1 | |
| SCHEMBL18157054 | 0.76 | MEN1 (0.39) | MEN1KMT2A | |
| SCHEMBL18882502 | 0.73 | ALDH1A1 (0.39) | MEN1KMT2ATP53KDM4EALDH1A1 | |
| SCHEMBL31513757 | 0.71 | KDM4E (0.35) | MEN1KMT2AARKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | claimed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | claimed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | claimed |
| EP-2984070-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | Mankind Research Centre (IN) | 2016-02-17 | — | — | EP | claimed |
| WO-2014167507-A1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND RESEARCH CENTRE (IN) | 2014-10-16 | — | — | WO | claimed |
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2019-03-26 | — | — | US | disclosed |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | MANKIND PHARMA LTD. (IN) | 2018-04-26 | — | — | US | disclosed |
| EP-2984070-B1 | N-HALOALKYLINDOLINE INTERMEDIATES, THEIR PROCESS AND USE IN PREPARATION OF SILODOSIN AND ITS DERIVATIVES | MANKIND PHARMA LTD (IN) | 2018-01-17 | — | — | EP | disclosed |
| US-9862681-B2 | N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives | MANKIND RESEARCH CENTRE (IN) | 2018-01-09 | — | — | US | disclosed |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | MANKIND PHARMA LTD (IN) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239833-B2 | Intermediates, their process and use in preparation of selective α1-adrenoceptor antagonists, Silodosin | ADRA1D, ADRB1, ADRA1A | CYP11B2 71/4885MEN1 2109/4885KMT2A 3333/4885 |
| US-20160046577-A1 | N-Haloalkylindoline Intermediates, Their Process And Use In Preparation of Silodosin And its Derivatives | ADRA1D, ADRA1A, ADRB1 | CYP11B2 534/4885MEN1 2015/4885KMT2A 3543/4885 |
| US-20180111901-A1 | Novel Intermediates, their Process And Use In Preparation of Selective a1-Adrenoceptor Antagonists, Silodosin | ADRA1D, ADRA1A, ADRB1 | CYP11B2 87/4885MEN1 1463/4885KMT2A 3310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.